BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kandel S, Adhikary P, Li G, Cheng K. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. Cancer Lett 2021;510:67-78. [PMID: 33895262 DOI: 10.1016/j.canlet.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, Dorillo E, Rompietti C, Adamo FM, Ruggeri L, Di Ianni M, Rosati E. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Int J Mol Sci 2021;22:6665. [PMID: 34206399 DOI: 10.3390/ijms22136665] [Reference Citation Analysis]
2 Bailly C, Thuru X, Quesnel B. Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter? Cancers (Basel) 2021;13:6365. [PMID: 34944985 DOI: 10.3390/cancers13246365] [Reference Citation Analysis]
3 Mittelberger J, Seefried M, Franitza M, Garrido F, Ditsch N, Jeschke U, Dannecker C. The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia—A Narrative Review. Medicina 2022;58:157. [DOI: 10.3390/medicina58020157] [Reference Citation Analysis]
4 Hong J, Xia L, Huang Z, Yuan X, Liang X, Dai J, Wu Z, Liang L, Ruan M, Long Z, Cheng X, Chen X, Ni J, Ge J, Li Q, Zeng Q, Xia R, Wang Y, Yang M. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes. Front Oncol 2022;12:879471. [DOI: 10.3389/fonc.2022.879471] [Reference Citation Analysis]